MDP — Medexus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- CA$129.38m
- CA$144.11m
- $108.33m
Brief: Medexus Announces Record Fiscal Q1 2023 Revenue Of Us$23.0 Million, A 33% Increase Versus Fiscal Q1 2022
Brief: Medexus Pharmaceuticals Says Treosulfan NDA Resubmitted To FDA
Brief: Medexus Pharmaceuticals Sees Q4 Revenue Up 15 Percent
Brief: Medexus Announces Resubmission Of Treosulfan NDA
Brief: Medexus Pharmaceuticals Announces Deal For Gleolan In The United States
Brief: Medexus Pharmaceuticals Announces Normal Course Issuer Bid, Or Ncib, For Convertible Debentures
Brief: Medexus Pharmaceuticals Announces Clear Path To FDA Decision Following Medac’S Type A Meeting With FDA On Treosulfan
Brief: Medexus Pharma Reports Results For Three- And Six-Month Periods Ending Sept 30
Brief: Medexus Pharma Announces Type A Meeting With FDA Granted For Treosulfan
Brief: Medexus Announces Expanded Availability Of Trecondyv In Canada
Canada Research Roundup: Ayr Wellness, Doman Building Materials Group, Medexus Pharmaceuticals
Brief: Medexus Pharmaceuticals Reports Financial And Operational Results For First Quarter Fiscal 2022
Brief: Medexus Appoints New CFO
Brief: Medexus Receives Notice Of Compliance To Commercialize Treosulfan In Canada
Brief: Medexus Revenue Increases 43.5% To A Record US$79.7 Million For Fiscal 2021
Brief: Medexus Announces Graduation To The Toronto Stock Exchange
Brief: Medexus Announces Amendments To Its Credit Agreements
Brief: Medexus Posts Record Revenue Of $31.5 Mln For Q3 Fiscal 2021
Brief: Medexus Announces Upsize To Previously Announced Bought Deal Public Offering